Thank you for Subscribing to Life Science Review Weekly Brief
Gelteq appoints James Pekarsky as CFO.
FREMONT, CA: Gelteq Pty Ltd, a global leader in ingestible gel technology for healthcare, nutrition, and sports, appoints James Pekarsky as the Chief Financial Officer, as the company accelerates its global launch, including its first significant entry into the United States market.
Pekarsky offers over 30 years of finance and executive experience from biotechnology and technology companies to Gelteq. This includes 15 years as CEO and CFO of publicly traded companies, five years as general manager of large US-based companies operating in Europe, and ten years as a founder and CEO of start-up companies in Silicon Valley, where he led several financings, initial public offerings, acquisitions, and exits.
Pekarsky formerly co-founded and ran BioPharmX, a NYSE-listed business focused on new pharmaceutical delivery technologies, where he led several financings and the firm's initial public offering. He has since worked as an executive consultant for private firms in the medical and high-tech sectors, advising on all aspects of finance and operations, including fundraising, mergers and acquisitions, business development, and corporate governance.
“We welcome Jim’s extensive financial knowledge and operational experience, particularly his success with developing novel pharma delivery systems,” states Simon Szewach, Gelteq co-founder and executive chairman. “His proven capabilities and knowhow greatly complement our fast-track for growth and our expanding team of industry pioneers.
We expect Jim to play an essential role as we continue to ramp our sales and marketing, manufacturing and licensing programs on a global scale, as well as pursue opportunities in the capital markets to accelerate this growth.”
Pekarsky served as CFO of several successful semiconductor companies before co-founding BioPharmX, including Wavesat (acquired by Cavium Networks/Marvell), SiliconBlue Technologies (developed by Lattice), Mosys (a Nasdaq-listed company), AccelChip (acquired by Xilinx), and Virage Logic Corporation (acquired by Synopsis). He also oversaw Virage's Nasdaq initial public offering.
“I see tremendous market opportunities and multiple ways for Gelteq to capitalize on its extensive IP portfolio and growing number of international patents that support its innovative gel delivery system,” comments Pekarsky. “The sports, health and wellness, and pharma partnerships the company has formed are impressive and support its commercial rollout. Im looking forward to supporting the company’s continued growth and international expansion.”
Pekarsky earned a bachelor's degree in accounting from the Indiana University of Pennsylvania and a master's degree in business administration from Golden Gate University in San Francisco.